Join
Live feed
·
PRReleasevia Quantisnow
Summit Therapeutics Inc. logo

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

ByQuantisnow·Wall Street's wire, on your screen.
SMMT· Summit Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SMMT (Summit Therapeutics Inc.) and more on Quantisnow.